Abstract
The objective of this study was to compare the efficacy of rizatriptan and ibuprofen in migraine. The study was a randomised placebo-controlled trial in a tertiary care teaching hospital. Migraine patients with <8 attacks/months were included. One hundred and fifty-five migraine patients were randomised to rizatriptan 10 mg (53), ibuprofen 400 mg (52) and placebo (50). Efficacy was assessed by headache relief, and headache freedom at 2 h and 24 h. Two-hour headache relief, was noted in 73% in rizatriptan, 53.8% in ibuprofen and 8% in placebo groups. Headache freedom was achieved in 37.7% in rizatriptan, 30.8% in ibuprofen and 2% in placebo groups. Rizatriptan was superior to ibuprofen and placebo in relieving headache at 2 h but not at 24 h. Side effects were noted in 9 patients in rizatriptan, 8 in ibuprofen and 3 in placebo, all of which were nonsignificant. Rizatriptan and ibuprofen are superior to placebo. Rizatriptan is superior to ibuprofen in relieving headache, associated symptoms and functional disability.
Keywords: Migraine, Rizatriptan, Acute attack, Randomised controlled trial, Treatment
Full Text
The Full Text of this article is available as a PDF (51.7 KB).
References
- 1.Misra U.K., Jose M., Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. Postgrad Med J. 2004;80:720–723. doi: 10.1136/pgmj.2003.012393. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Silberstein S.D. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754–762. doi: 10.1212/wnl.55.6.754. [DOI] [PubMed] [Google Scholar]
- 3.Rocha J.L., Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet. 2001;357:1946–1947. doi: 10.1016/S0140-6736(00)05083-2. [DOI] [PubMed] [Google Scholar]
- 4.Hamalainen M.L., Hoppu K., Valkeila E., Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997;48:103–107. doi: 10.1212/wnl.48.1.103. [DOI] [PubMed] [Google Scholar]
- 5.Havaka-Kanniainen H. Treatment of acute migraine attack: ibuprofen and placebo compared. Headache. 1989;29:507–509. doi: 10.1111/j.1526-4610.1989.hed2908507.x. [DOI] [PubMed] [Google Scholar]
- 6.Caklwell J., Holt P. MK 0966, a specific COX 2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26 week control trial. Arthritis Rheum. 1998;41:S83. [Google Scholar]
- 7.Codispoti J.R., Prior M.J., Fu M., et al. Efficacy of nonprescription doses of ibuprofen for treating migraine headache: a randomized controlled trial. Headache. 2001;41:665–679. doi: 10.1046/j.1526-4610.2001.041007665.x. [DOI] [PubMed] [Google Scholar]
- 8.Adelman J.U., Lipton R.B., Ferrari M.D., et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology. 2001;57:1377–1383. doi: 10.1212/wnl.57.8.1377. [DOI] [PubMed] [Google Scholar]
- 9.Christie S., Gobel H., Mateos V., Rizatriptan-Ergotamine/Caffeine Preference Study Group et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol. 2003;49:20–29. doi: 10.1159/000067018. [DOI] [PubMed] [Google Scholar]
- 10.Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;7([Suppl7]):1–96. [PubMed] [Google Scholar]
- 11.Kramer M.S., Matzura-Wolfe D., Polis A., et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology. 1998;51:773–781. doi: 10.1212/wnl.51.3.773. [DOI] [PubMed] [Google Scholar]
- 12.Kolster R., Nestvold K., Vilming S.T. A double blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia. 1992;12:169–171. doi: 10.1046/j.1468-2982.1992.1203169.x. [DOI] [PubMed] [Google Scholar]
- 13.Kellstein D.E., Lipton R.B., Geetha R., et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized double blind, placebo-controlled, dose ranging study. Cephalalgia. 2000;20:233–243. doi: 10.1046/j.1468-2982.2000.00055.x. [DOI] [PubMed] [Google Scholar]
- 14.Diener H.C., Bussone G., Liano H., et al. EMSASI Study Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004;24:947–954. doi: 10.1111/j.1468-2982.2004.00783.x. [DOI] [PubMed] [Google Scholar]
- 15.Smith T.R., Sunshine A., Stark S.R., et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45:983–991. doi: 10.1111/j.1526-4610.2005.05178.x. [DOI] [PubMed] [Google Scholar]
- 16.Geraud G., Compagnon A., Rossi A., COZAM Study Group Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol. 2002;47:88–98. doi: 10.1159/000047959. [DOI] [PubMed] [Google Scholar]